anhydrous enol-oxaloacetate + temozolomide

**Anhydrous enol-oxaloacetate + temozolomide** is an investigational combination therapy consisting of the metabolic modifier enol-oxaloacetate (anhydrous form) and the alkylating anti-neoplastic small molecule temozolomide. Temozolomide is an oral imidazotetrazine prodrug that alkylates and methylates guanine residues in DNA, inducing DNA damage, cell cycle arrest, and apoptosis, primarily used in glioblastoma and anaplastic astrocytoma[1][2][6]. Enol-oxaloacetate is a metabolic intermediate in the tricarboxylic acid (TCA) cycle; anhydrous enol-oxaloacetate has been explored as a dietary supplement and may support metabolic reprogramming in cancer by affecting key steps in the TCA cycle and modulating NAD+/NADH redox balance, but its utility as a pharmaceutical remains experimental and is subject to ongoing research. This combination has been considered as a strategy to potentiate anti-tumor responses, especially in glioma and primary brain malignancies, by combining metabolic modulation (via oxaloacetate) and direct DNA damage (via temozolomide). Development status is limited and primarily in early-phase studies or preclinical research.

Other names

anhydrous enol-oxaloacetate plus temozolomideenol-oxaloacetate anhydrous with temozolomide